India's GLP-1 generics market,
tracked independently.
Since semaglutide's Indian patent expiry in March 2026, press reports have expected more than 50 brand names from over 40 manufacturers across the market through 2026 — an entry expectation, not a count of approvals or launches. Our tracker lists 20 generic brands, each linked to its source, from 12 manufacturers and co-marketing partners, and prices 18 of them at ₹1,290–₹8,000 per month — a 6.2× spread for the same molecule, against ₹3,999–₹16,400 for Novo Nordisk's own brands. No independent layer exists to compare brands, prices, or legitimacy. We are building that layer: educational, data-first, and seller-neutral.
The world's biggest natural experiment in GLP-1 access
When the semaglutide patent expired in India, dozens of manufacturers entered within weeks. Prices fell by an order of magnitude compared to Western list prices. The shift is already visible in share data: press reports put semaglutide — branded and generic combined — at 33% of India's GLP-1 market in March 2026, up from 25% in February, while Eli Lilly's Mounjaro (tirzepatide) fell from 71% to 64% (eMarketer, April 2026, citing Bloomberg). That solved access — and created a new problem: with dozens of brands at wildly different prices and no independent quality or legitimacy signal, patients and doctors are choosing blind.
40+
manufacturers press reports expected to enter India's generic semaglutide market through 2026 (Business Today, March 2026) — an entry expectation, not a launch count. Our tracker below lists 20 generic brands, each linked to its source
₹1,290–8k
monthly cost across priced generic brands — a 6.2× spread for the same molecule (the widely-quoted ₹220 floor is per shot, not per month)
13/25
brands whose regulatory status we could confirm from a public source — the rest are a documented gap, not a clean bill of health
Why legitimacy is the real question
These are biologic medications that must be kept between 2°C and 8°C from manufacturer to fridge — and a heat-compromised pen looks identical to a good one. Combine an Indian summer, an un-insulated delivery bag, and a price war, and the cheapest listing is not automatically the best value. Independent data on brands, sourcing, and handling standards is the only way patients and doctors can tell the difference.
A daily pipeline, not a one-off report
Regulatory decisions
News coverage of CDSCO approvals, advisories and enforcement actions, and news coverage of EMA/MHRA/WHO safety actions — captured daily by our pipeline and stored as structured, dated data points. FDA FAERS report shares are also in the corpus, but as a dated snapshot rather than a daily feed: the newest stored FAERS row is 2026-08-13. We also scan CDSCO's own Not-of-Standard-Quality drug register directly, daily, for every brand we track — a separate legitimacy check, kept apart from the side-effects corpus.
Indian clinical literature
India-specific studies and case reports from PubMed, tracked separately so Indian real-world evidence isn't drowned out by Western trial data.
Market and launch signals
Brand launches, price moves, and manufacturing announcements from Indian news sources — the raw material for an independent picture of the world's fastest-moving GLP-1 generics market.
Safety reports
Side-effect data across 15 effects and 9 medications, with clinical-trial and real-world rates kept on separate tracks and never blended. Methodology published in full.
India semaglutide brand tracker
25 brands (20 generic) from 15 manufacturers, with monthly price bands in INR, formulation, DCGI status, and a verification level on every row. Compiled from public sources only — 21 rows are corroborated by two or more independent sources, 4 rest on one and are labelled accordingly. Version 2026-08-25.v3, compiled 2026-08-25.
| Brand | Manufacturer | Type | Formulation | ₹ / month | Sources |
|---|---|---|---|---|---|
| Semanat | Natco Pharma | generic | injection, multi-dose vial | ₹1,290–₹1,750as of 2026-03 | 2+ sources |
| SUNDAE | Eris Lifesciences (with Natco Pharma) | generic | injection, multi-dose vial (2 mg/1.5 ml and 4 mg/3 ml); pen device added April 2026 | ₹1,290–₹4,500as of 2026-08 | 2+ sources |
| GLIPIQ | Glenmark Pharmaceuticals | generic | injection, vial and pre-filled pen | ₹1,300–₹1,760as of 2026-03 | 2+ sources |
| Semasize | Alkem Laboratories | generic | injection, pre-filled disposable and reusable pen options | ₹1,800–₹3,500as of 2026-03 | 2+ sources |
| Obesema | Alkem Laboratories | generic | injection, pre-filled disposable and reusable pen options | ₹1,800as of 2026-03 | 2+ sources |
| Hepaglide | Alkem Laboratories | generic | injection, pre-filled disposable and reusable pen options | ₹1,800as of 2026-03 | 2+ sources |
| Semaglyn | Zydus Lifesciences | generic | injection, reusable multi-dose pen | ₹2,200–₹5,500as of 2026-03 | 2+ sources |
| Mashema | Zydus Lifesciences | generic | injection, reusable multi-dose pen | ₹2,200as of 2026-03 | 2+ sources |
| Alterme | Zydus Lifesciences | generic | injection, reusable multi-dose pen | ₹2,200as of 2026-03 | 2+ sources |
| Semanext | Lupin (semi-exclusive co-marketing of Zydus product) | generic | injection | ₹2,200as of 2026-08 | 2+ sources |
| Livarise | Lupin (semi-exclusive co-marketing of Zydus product) | generic | injection | ₹2,200as of 2026-08 | 2+ sources |
| Sematrinity | Sun Pharma | generic | injection, multi-dose pen | ₹3,000–₹5,200as of 2026-03 | 2+ sources |
| Noveltreat | Sun Pharma | generic | injection, pre-filled pen | ₹3,600–₹8,000as of 2026-03 | 2+ sources |
| Semabest | MSN Laboratories | generic | injection | ₹3,990as of 2026-08 | 1 source |
| Sembolic | Torrent Pharmaceuticals (injectable co-marketed with Zydus Lifesciences) | generic | injection | ₹3,999as of 2026-03 | 2+ sources |
| Wegovy | Novo Nordisk | innovator | injection, weekly pen | ₹3,999–₹16,400as of 2026-08 | 2+ sources |
| Semafull | Natco Pharma | generic | injection, pen device | ₹4,000–₹4,500as of 2026-03 | 2+ sources |
| Obeda | Dr Reddy's Laboratories | generic | injection, pre-filled disposable pen | ₹4,200as of 2026-03 | 2+ sources |
| Usema | USV (co-marketing with Dr Reddy's) | generic | injection | ₹4,200as of 2026-08 | 1 source |
| Ozempic | Novo Nordisk | innovator | injection, weekly pen | ₹5,660–₹9,100as of 2026-08 | 2+ sources |
| Semalix | Torrent Pharmaceuticals | generic | oral, daily tablet — India's FIRST generic oral semaglutide | not published | 2+ sources |
| Samakind | Mankind Pharma | generic | injection | not published | 2+ sources |
| Rybelsus | Novo Nordisk | innovator | oral, daily tablet | not published | 2+ sources |
| Extensior | Abbott (co-marketing Novo semaglutide) | innovator-comarketed | — | not published | 1 source |
| Poviztra | Emcure (co-marketing Novo semaglutide) | innovator-comarketed | — | not published | 1 source |
How to read the prices
Everything is normalised to INR per month. Where a source quoted a per-shot or per-week figure, it was converted and the original kept in the CSV's priceINRPerShot and priceNote columns. This matters: the ₹220 figure quoted widely in the press is one vial shot, not a month of treatment. Prices are launch-window or as-listed on the stated date and move frequently.
What this dataset does not yet cover
- Strength-level (per-mg) pricing for like-for-like comparison
- DCGI status for 12 of 25 rows — CDSCO databases are the next source
- Batch alerts, recalls, and not-of-standard-quality reports — the legitimacy layer this market actually lacks
- Brands beyond these 25: press reports expect more than 50 brand names from over 40 manufacturers to enter through 2026 (Business Today, March 2026) — an entry expectation, not a confirmed count
Citation: Magistra, “India semaglutide brand/price/legitimacy dataset”, version 2026-08-25.v3, CC BY 4.0. Methodology and the wider outcomes database: /methodology . Continuous dated updates to this tracker are what data subscriptions fund. Data, not investment advice.
Get the updates to this tracker
The dataset above is version 2026-08-25.v3. We are working through the gaps listed beside it — CDSCO status for the unconfirmed rows, the brands not yet captured, and a batch/recall alert layer. Leave your email and we'll write when a new version lands.
Notify me on new versions
Dataset releases only. No marketing, no spam.
This page is educational and informational only. Magistra does not sell, dispense, prescribe, promote, or deliver any medication, and does not provide medical advice or clinical services in India. GLP-1 medications are prescription-only and must be used solely under the supervision of a licensed physician. Nothing here is an endorsement of any brand or a recommendation to start, stop, or switch any medication. Indian law (CDSCO) prohibits the promotion of these medications to consumers; Magistra publishes independent data and analysis, not promotion.